Mutation and expression analysis of the p73 gene in prostate cancer

Akira Yokomizo, Ming Mai, David G. Bostwick, Donald J. Tindall, Junqi Qian, Liang Cheng, Robert B. Jenkins, David I. Smith, Wanguo Liu

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. p53 is the most highly mutated tumor suppressor gene in human cancers. Recently, p73, a first homologue of p53, was identified and considered to be an imprinted tumor suppressor gene. Thus, we analyzed the possible role of p73 in human prostate cancers. METHODS. We investigated the expression levels and expressed allelotypes and searched for mutations in the p73 gene in 27 primary prostate cancers with matched normal tissues as well as in four prostate cell lines. RESULTS. Allelic expression analysis using polymorphisms in exons 2 and 5 revealed that p73 is biallelically expressed in both normal and tumor tissues, suggesting that p73 is not imprinted in prostate tissues. Quantitative PCR demonstrated that p73 expression is the same in both normal and tumor prostate tissues. Denaturing high-performance liquid chromatography and DNA sequencing revealed that there were no tumor- specific mutations in the p73 gene at the genomic level. CONCLUSIONS. These data indicate that alterations of p73, including mutations, changes in message abundance, and changes in allelic expression, are likely to be rare in early-stage prostate cancer, and that p73 could be a tissue-specific imprinting gene.

Original languageEnglish (US)
Pages (from-to)94-100
Number of pages7
JournalProstate
Volume39
Issue number2
DOIs
StatePublished - Apr 1 1999
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Mutation
Prostate
Genes
Tumor Suppressor Genes
Neoplasms
DNA Sequence Analysis
Exons
High Pressure Liquid Chromatography
Cell Line
Polymerase Chain Reaction

Keywords

  • Allelic expression
  • Imprinting
  • Mutation
  • P73
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Mutation and expression analysis of the p73 gene in prostate cancer. / Yokomizo, Akira; Mai, Ming; Bostwick, David G.; Tindall, Donald J.; Qian, Junqi; Cheng, Liang; Jenkins, Robert B.; Smith, David I.; Liu, Wanguo.

In: Prostate, Vol. 39, No. 2, 01.04.1999, p. 94-100.

Research output: Contribution to journalArticle

Yokomizo, A, Mai, M, Bostwick, DG, Tindall, DJ, Qian, J, Cheng, L, Jenkins, RB, Smith, DI & Liu, W 1999, 'Mutation and expression analysis of the p73 gene in prostate cancer', Prostate, vol. 39, no. 2, pp. 94-100. https://doi.org/10.1002/(SICI)1097-0045(19990501)39:2<94::AID-PROS3>3.0.CO;2-W
Yokomizo, Akira ; Mai, Ming ; Bostwick, David G. ; Tindall, Donald J. ; Qian, Junqi ; Cheng, Liang ; Jenkins, Robert B. ; Smith, David I. ; Liu, Wanguo. / Mutation and expression analysis of the p73 gene in prostate cancer. In: Prostate. 1999 ; Vol. 39, No. 2. pp. 94-100.
@article{e97afbb21318464c8ca4a1ded89c3e25,
title = "Mutation and expression analysis of the p73 gene in prostate cancer",
abstract = "BACKGROUND. p53 is the most highly mutated tumor suppressor gene in human cancers. Recently, p73, a first homologue of p53, was identified and considered to be an imprinted tumor suppressor gene. Thus, we analyzed the possible role of p73 in human prostate cancers. METHODS. We investigated the expression levels and expressed allelotypes and searched for mutations in the p73 gene in 27 primary prostate cancers with matched normal tissues as well as in four prostate cell lines. RESULTS. Allelic expression analysis using polymorphisms in exons 2 and 5 revealed that p73 is biallelically expressed in both normal and tumor tissues, suggesting that p73 is not imprinted in prostate tissues. Quantitative PCR demonstrated that p73 expression is the same in both normal and tumor prostate tissues. Denaturing high-performance liquid chromatography and DNA sequencing revealed that there were no tumor- specific mutations in the p73 gene at the genomic level. CONCLUSIONS. These data indicate that alterations of p73, including mutations, changes in message abundance, and changes in allelic expression, are likely to be rare in early-stage prostate cancer, and that p73 could be a tissue-specific imprinting gene.",
keywords = "Allelic expression, Imprinting, Mutation, P73, Prostate cancer",
author = "Akira Yokomizo and Ming Mai and Bostwick, {David G.} and Tindall, {Donald J.} and Junqi Qian and Liang Cheng and Jenkins, {Robert B.} and Smith, {David I.} and Wanguo Liu",
year = "1999",
month = "4",
day = "1",
doi = "10.1002/(SICI)1097-0045(19990501)39:2<94::AID-PROS3>3.0.CO;2-W",
language = "English (US)",
volume = "39",
pages = "94--100",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Mutation and expression analysis of the p73 gene in prostate cancer

AU - Yokomizo, Akira

AU - Mai, Ming

AU - Bostwick, David G.

AU - Tindall, Donald J.

AU - Qian, Junqi

AU - Cheng, Liang

AU - Jenkins, Robert B.

AU - Smith, David I.

AU - Liu, Wanguo

PY - 1999/4/1

Y1 - 1999/4/1

N2 - BACKGROUND. p53 is the most highly mutated tumor suppressor gene in human cancers. Recently, p73, a first homologue of p53, was identified and considered to be an imprinted tumor suppressor gene. Thus, we analyzed the possible role of p73 in human prostate cancers. METHODS. We investigated the expression levels and expressed allelotypes and searched for mutations in the p73 gene in 27 primary prostate cancers with matched normal tissues as well as in four prostate cell lines. RESULTS. Allelic expression analysis using polymorphisms in exons 2 and 5 revealed that p73 is biallelically expressed in both normal and tumor tissues, suggesting that p73 is not imprinted in prostate tissues. Quantitative PCR demonstrated that p73 expression is the same in both normal and tumor prostate tissues. Denaturing high-performance liquid chromatography and DNA sequencing revealed that there were no tumor- specific mutations in the p73 gene at the genomic level. CONCLUSIONS. These data indicate that alterations of p73, including mutations, changes in message abundance, and changes in allelic expression, are likely to be rare in early-stage prostate cancer, and that p73 could be a tissue-specific imprinting gene.

AB - BACKGROUND. p53 is the most highly mutated tumor suppressor gene in human cancers. Recently, p73, a first homologue of p53, was identified and considered to be an imprinted tumor suppressor gene. Thus, we analyzed the possible role of p73 in human prostate cancers. METHODS. We investigated the expression levels and expressed allelotypes and searched for mutations in the p73 gene in 27 primary prostate cancers with matched normal tissues as well as in four prostate cell lines. RESULTS. Allelic expression analysis using polymorphisms in exons 2 and 5 revealed that p73 is biallelically expressed in both normal and tumor tissues, suggesting that p73 is not imprinted in prostate tissues. Quantitative PCR demonstrated that p73 expression is the same in both normal and tumor prostate tissues. Denaturing high-performance liquid chromatography and DNA sequencing revealed that there were no tumor- specific mutations in the p73 gene at the genomic level. CONCLUSIONS. These data indicate that alterations of p73, including mutations, changes in message abundance, and changes in allelic expression, are likely to be rare in early-stage prostate cancer, and that p73 could be a tissue-specific imprinting gene.

KW - Allelic expression

KW - Imprinting

KW - Mutation

KW - P73

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0033119215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033119215&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19990501)39:2<94::AID-PROS3>3.0.CO;2-W

DO - 10.1002/(SICI)1097-0045(19990501)39:2<94::AID-PROS3>3.0.CO;2-W

M3 - Article

VL - 39

SP - 94

EP - 100

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -